1. Home
  2. RVPH vs LEE Comparison

RVPH vs LEE Comparison

Compare RVPH & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • LEE
  • Stock Information
  • Founded
  • RVPH 2006
  • LEE 1890
  • Country
  • RVPH United States
  • LEE United States
  • Employees
  • RVPH N/A
  • LEE N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • LEE Newspapers/Magazines
  • Sector
  • RVPH Health Care
  • LEE Consumer Discretionary
  • Exchange
  • RVPH Nasdaq
  • LEE Nasdaq
  • Market Cap
  • RVPH 88.0M
  • LEE 90.6M
  • IPO Year
  • RVPH N/A
  • LEE N/A
  • Fundamental
  • Price
  • RVPH $1.84
  • LEE $11.55
  • Analyst Decision
  • RVPH Strong Buy
  • LEE
  • Analyst Count
  • RVPH 5
  • LEE 0
  • Target Price
  • RVPH $11.40
  • LEE N/A
  • AVG Volume (30 Days)
  • RVPH 1.7M
  • LEE 24.6K
  • Earning Date
  • RVPH 11-14-2024
  • LEE 02-06-2025
  • Dividend Yield
  • RVPH N/A
  • LEE N/A
  • EPS Growth
  • RVPH N/A
  • LEE N/A
  • EPS
  • RVPH N/A
  • LEE N/A
  • Revenue
  • RVPH N/A
  • LEE $600,264,000.00
  • Revenue This Year
  • RVPH N/A
  • LEE N/A
  • Revenue Next Year
  • RVPH N/A
  • LEE N/A
  • P/E Ratio
  • RVPH N/A
  • LEE N/A
  • Revenue Growth
  • RVPH N/A
  • LEE N/A
  • 52 Week Low
  • RVPH $0.60
  • LEE $7.57
  • 52 Week High
  • RVPH $4.83
  • LEE $19.63
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 48.62
  • LEE 33.15
  • Support Level
  • RVPH $1.97
  • LEE $11.50
  • Resistance Level
  • RVPH $2.14
  • LEE $13.69
  • Average True Range (ATR)
  • RVPH 0.14
  • LEE 0.86
  • MACD
  • RVPH -0.01
  • LEE -0.07
  • Stochastic Oscillator
  • RVPH 40.43
  • LEE 5.21

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

Share on Social Networks: